Transcode Therapeutics Ownership
| RNAZ Stock | USD 9.44 0.25 2.58% |
Shares in Circulation | First Issued 2019-12-31 | Previous Quarter 356.1 K | Current Value 172.3 K | Avarage Shares Outstanding 127.9 K | Quarterly Volatility 201.2 K |
Transcode | Build AI portfolio with Transcode Stock |
Transcode Stock Ownership Analysis
The company has price-to-book ratio of 0.76. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Transcode Therapeutics recorded a loss per share of 792.4. The entity had not issued any dividends in recent years. The firm had 1:28 split on the 15th of May 2025. TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. The company was incorporated in 2016 and is based in Boston, Massachusetts. Transcode Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 8 people. To find out more about Transcode Therapeutics contact Thomas MBA at 857-837-3099 or learn more at https://www.transcodetherapeutics.com.Transcode Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Transcode Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Transcode Therapeutics backward and forwards among themselves. Transcode Therapeutics' institutional investor refers to the entity that pools money to purchase Transcode Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Fmr Inc | 2025-03-31 | 25.0 | Bank Of America Corp | 2025-03-31 | 6.0 | Captrust Financial Advisors | 2024-12-31 | 0.0 | Jane Street Group Llc | 2024-12-31 | 0.0 | Sheets Smith Wealth Management | 2024-12-31 | 0.0 | Private Capital Management Llc | 2024-12-31 | 0.0 | Geode Capital Management, Llc | 2024-12-31 | 0.0 | Anson Funds Management Lp | 2025-03-31 | 1.5 M | Ubs Group Ag | 2025-03-31 | 263.9 K | Sabby Management Llc | 2025-03-31 | 229.1 K | Warberg Asset Management Llc | 2025-03-31 | 50 K |
Transcode Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Transcode Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Transcode Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Transcode Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Transcode Therapeutics Outstanding Bonds
Transcode Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Transcode Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Transcode bonds can be classified according to their maturity, which is the date when Transcode Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| TRANSCANADA PIPELINES LTD Corp BondUS893526DF78 | View | |
| TRANSCANADA PIPELINES LTD Corp BondUS893526DJ90 | View | |
| TRANSATLANTIC HLDGS INC Corp BondUS893521AB05 | View | |
| TRANSCONTINENTAL GAS PIPE Corp BondUS893574AB92 | View | |
| TRANSCONTINENTAL GAS PIPE Corp BondUS893574AH62 | View | |
| US893574AF07 Corp BondUS893574AF07 | View | |
| TRPCN 55 15 SEP 79 Corp BondUS89356BAE83 | View | |
| TRPCN 5875 15 AUG 76 Corp BondUS89356BAB45 | View |
Transcode Therapeutics Corporate Filings
| 15th of July 2025 Other Reports | ViewVerify | |
8K | 13th of June 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 14th of May 2025 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
10K | 30th of April 2025 An amendment to a previously filed Form 10-K | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Transcode Stock Analysis
When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.